Europe Botulinum Toxin In Urology Market Size & Outlook
Europe botulinum toxin in urology market, 2018-2030 (US$M)
Related Markets
Europe botulinum toxin in urology market highlights
- The Europe botulinum toxin in urology market generated a revenue of USD 267.1 million in 2023.
- The market is expected to grow at a CAGR of 5.6% from 2024 to 2030.
- In terms of segment, overactive bladder was the largest revenue generating application in 2023.
- Overactive Bladder is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Sweden is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 267.1 million |
| Market revenue in 2030 | USD 392.1 million |
| Growth rate | 5.6% (CAGR from 2023 to 2030) |
| Largest segment | Overactive bladder |
| Fastest growing segment | Overactive Bladder |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Overactive Bladder, Neurogenic Detrusor Overactivity |
| Key market players worldwide | AbbVie Inc, Merz Pharma, Ipsen SA, Galderma Group AG Registered Shares, Allergan, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.6% of the global botulinum toxin in urology market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 394.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Botulinum Toxin In Urology Market Scope
Botulinum Toxin In Urology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe botulinum toxin in urology market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to botulinum toxin in urology market will help companies and investors design strategic landscapes.
Overactive bladder was the largest segment with a revenue share of 66.57% in 2023. Horizon Databook has segmented the Europe botulinum toxin in urology market based on overactive bladder, neurogenic detrusor overactivity covering the revenue growth of each sub-segment from 2018 to 2030.
- Europe Botulinum Toxin In Urology Application Outlook (Revenue, USD Million, 2018-2030)
- Overactive Bladder
- Neurogenic Detrusor Overactivity
- Europe Botulinum Toxin In Urology End Use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Urology Clinics
Reasons to subscribe to Europe botulinum toxin in urology market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe botulinum toxin in urology market databook
-
Our clientele includes a mix of botulinum toxin in urology market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe botulinum toxin in urology market, including forecasts for subscribers. This continent databook contains high-level insights into Europe botulinum toxin in urology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe botulinum toxin urology market report size, by country, 2018-2030 (US$M)
Europe Botulinum Toxin In Urology Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
